A Single Infusion Drug That Might Lower Cholesterol for 18 Months: What Lilly Just Reported

Eli Lilly and Company shared new Phase 1b results for a drug called VERVE-102.

The main idea is pretty big: a single intravenous infusion of this experimental treatment may reduce LDL cholesterol for a long time, potentially up to 18 months or more in some participants.

The data came from a study called Heart-2 and was presented at a major scientific meeting and also published in a top medical journal.

What VERVE-102 is trying to do

VERVE-102 is not a regular cholesterol pill.

It is a gene-editing therapy designed to act directly inside the body.

The target is a gene called PCSK9, which plays a major role in controlling cholesterol levels in the blood.

The drug is designed to turn off this gene in liver cells.

Once that gene is turned off, the body produces less PCSK9 protein, which leads to lower LDL cholesterol.

So the idea is simple in theory: change the gene once, and get long-lasting cholesterol reduction.

Why PCSK9 matters in heart disease

PCSK9 is not just some random protein.

It is strongly linked to LDL cholesterol levels, which is the “bad cholesterol” people talk about in heart disease.

Lower PCSK9 levels usually mean lower LDL cholesterol.

In fact, some people are born with natural mutations that reduce PCSK9 activity. These people tend to have:

• Very low LDL cholesterol 

• Lower lifetime risk of heart disease 

• Fewer heart attacks overall 

So VERVE-102 is basically trying to mimic that natural protective situation.

What the Heart-2 trial tested

The Heart-2 study is a Phase 1b clinical trial.

It tested VERVE-102 in people who already have high cardiovascular risk, including:

• Heterozygous familial hypercholesterolemia (HeFH) 

• Premature coronary artery disease 

These are people who already struggle with high LDL cholesterol even while on standard treatment.

The trial gave participants a single intravenous infusion of the drug and then followed them over time.

What the results actually showed

The study included 35 participants in an interim analysis.

The key findings were:

• PCSK9 levels dropped between 51% and 88%, depending on dose 

• LDL cholesterol dropped in a dose-dependent way 

• LDL reductions ranged from about 9% to 62% across doses 

• Effects were sustained for up to 18 months in some participants 

So the important point is not just that cholesterol dropped, but that it stayed low for a long time after just one treatment.

What “dose-dependent” actually means here

Dose-dependent just means the higher the dose, the stronger the effect.

Lower doses showed smaller LDL reductions.

Higher doses showed much stronger LDL reductions, going above 60% in some groups.

So the drug seems to behave in a predictable way, which is usually a good sign in early clinical research.

Safety results so far

The safety profile reported in this early study looked manageable.

There were:

• No serious treatment-related adverse events 

• No dose-limiting toxic effects 

• Mild side effects like fatigue and infusion reactions 

No participants dropped out because of the treatment.

So at this stage, the safety data looks acceptable, but this is still early-phase research.

Why this approach is different from normal cholesterol drugs

Most cholesterol drugs today require ongoing use.

Statins, for example, are taken daily.

PCSK9 inhibitors are injectable but still need repeated dosing.

VERVE-102 is different because it is designed as a one-time treatment.

It tries to permanently switch off a gene in the liver.

So instead of managing cholesterol over years, the idea is to potentially reset cholesterol biology in a single procedure.

What gene editing is doing here

VERVE-102 uses a base editing system.

In simple terms, it delivers genetic instructions into liver cells that modify DNA at a specific location.

It includes:

• Messenger RNA that encodes a base editor 

• A guide RNA that targets the PCSK9 gene 

• A lipid nanoparticle that carries everything into liver cells 

Once inside, it makes a precise change in the gene so that PCSK9 production is reduced.

Who might benefit from this kind of treatment

The trial focused on people with high cardiovascular risk, including:

• Familial hypercholesterolemia (a genetic condition causing very high LDL) 

• Early-onset coronary artery disease 

These are patients who often struggle even with multiple cholesterol-lowering medications.

So this approach is aimed more at high-risk patients, not general cholesterol management at this stage.

How big the problem is

High LDL cholesterol is a major driver of heart disease worldwide.

Conditions like HeFH affect roughly 1 in 200 to 250 people.

And coronary artery disease is still one of the leading causes of death globally, affecting hundreds of millions of people.

So even small improvements in treatment durability could have a large impact at population level.

What happens next in development

The company plans to move forward quickly.

Eli Lilly and Company intends to start enrolling patients in a Phase 2 study of VERVE-102 by the end of this year.

Phase 2 will be important because it will test:

• Larger patient groups 

• Longer follow-up 

• More detailed safety and effectiveness data 

This is where the therapy either starts looking like a real future treatment or starts showing limitations.

Why scientists are paying attention

There are two main reasons this is getting attention.

First, the durability. Seeing LDL reduction last for up to 18 months after a single dose is unusual.

Second, the mechanism. This is one of the early examples of in vivo base editing being used in humans for cardiovascular disease.

That combination makes it more than just another cholesterol drug study.

Final takeaway

Here is the simple way to think about it.

VERVE-102 is an experimental gene-editing therapy that tries to permanently reduce LDL cholesterol by turning off the PCSK9 gene in the liver.

Early data from the Heart-2 trial shows:

• Significant LDL reduction 

• Long duration of effect 

• Acceptable short-term safety 

It is still early, and it is not a treatment you can get today.

But it represents a shift in thinking from daily cholesterol control to potentially one-time genetic treatment for cardiovascular risk.